MX2016010482A - Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer. - Google Patents
Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer.Info
- Publication number
- MX2016010482A MX2016010482A MX2016010482A MX2016010482A MX2016010482A MX 2016010482 A MX2016010482 A MX 2016010482A MX 2016010482 A MX2016010482 A MX 2016010482A MX 2016010482 A MX2016010482 A MX 2016010482A MX 2016010482 A MX2016010482 A MX 2016010482A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- combination
- proliferative disease
- cancer
- pi3k inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una combinación farmacéutica que comprende: ((a) un inhibidor específico de la isoforma alfa de la fosfatidilinositol-3-quinasa 2-amida 1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridi n-4-il]tiazol-2-il}-amida) del ácido (S)-pirrolidin-1,2-dicarboxíl ico o cualquier sal farmacéuticamente aceptable del mismo (b) un inhibidor de mTOR y (c) exemestano o cualquier sal farmacéuticamente aceptable del mismo, en particular para uso en el tratamiento o prevención de una enfermedad proliferativa; usos de tal combinación en la preparación de un medicamento para el tratamiento o prevención de una enfermedad proliferativa; composiciones farmacéuticas de la combinación de dichos agentes terapéuticos y métodos de tratamiento de una enfermedad proliferativa en un sujeto que comprende administrar a dicho sujeto una cantidad terapéuticamente eficaz de una combinación de este tipo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14305179 | 2014-02-11 | ||
PCT/IB2015/050993 WO2015121795A1 (en) | 2014-02-11 | 2015-02-10 | Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016010482A true MX2016010482A (es) | 2016-10-17 |
Family
ID=50115790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016010482A MX2016010482A (es) | 2014-02-11 | 2015-02-10 | Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer. |
Country Status (11)
Country | Link |
---|---|
US (2) | US20170165246A1 (es) |
EP (1) | EP3104890A1 (es) |
JP (1) | JP2017505345A (es) |
KR (1) | KR20160110963A (es) |
CN (1) | CN106061505A (es) |
AU (2) | AU2015216590A1 (es) |
BR (1) | BR112016014903A8 (es) |
CA (1) | CA2937504A1 (es) |
MX (1) | MX2016010482A (es) |
RU (1) | RU2016135413A (es) |
WO (1) | WO2015121795A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111150848B (zh) * | 2020-01-21 | 2022-02-15 | 中国药科大学 | Plagl2及其在肝癌中的应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8517360D0 (en) | 1985-07-09 | 1985-08-14 | Erba Farmitalia | Substituted androsta-1,4-diene-3,17-diones |
PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
GB9125660D0 (en) | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
ZA935111B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
CA2175215C (en) | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
AU687491B2 (en) | 1993-12-17 | 1998-02-26 | Novartis Ag | Rapamycin derivatives useful as immunosuppressants |
NZ311647A (en) | 1995-06-09 | 1999-11-29 | Novartis Ag | Rapamycin derivatives |
WO1998002441A2 (en) | 1996-07-12 | 1998-01-22 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
EP1212331B1 (en) | 1999-08-24 | 2004-04-21 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
PE20140601A1 (es) * | 2011-04-25 | 2014-05-24 | Novartis Ag | COMBINACION DE UN INHIBIDOR DE CINASA DE FOSFATIDIL-INOSITOL-3 (PI3K) Y UN INHIBIDOR DE mTOR |
US8980259B2 (en) * | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
-
2015
- 2015-02-10 WO PCT/IB2015/050993 patent/WO2015121795A1/en active Application Filing
- 2015-02-10 MX MX2016010482A patent/MX2016010482A/es unknown
- 2015-02-10 RU RU2016135413A patent/RU2016135413A/ru not_active Application Discontinuation
- 2015-02-10 BR BR112016014903A patent/BR112016014903A8/pt not_active IP Right Cessation
- 2015-02-10 CN CN201580008268.2A patent/CN106061505A/zh not_active Withdrawn
- 2015-02-10 KR KR1020167021587A patent/KR20160110963A/ko not_active Application Discontinuation
- 2015-02-10 EP EP15704384.5A patent/EP3104890A1/en not_active Withdrawn
- 2015-02-10 AU AU2015216590A patent/AU2015216590A1/en not_active Abandoned
- 2015-02-10 CA CA2937504A patent/CA2937504A1/en not_active Abandoned
- 2015-02-10 JP JP2016568158A patent/JP2017505345A/ja active Pending
- 2015-02-10 US US15/116,941 patent/US20170165246A1/en not_active Abandoned
-
2017
- 2017-10-26 AU AU2017251804A patent/AU2017251804A1/en not_active Abandoned
-
2018
- 2018-08-21 US US16/106,345 patent/US20180353495A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN106061505A (zh) | 2016-10-26 |
AU2017251804A1 (en) | 2017-11-16 |
RU2016135413A3 (es) | 2018-11-16 |
WO2015121795A1 (en) | 2015-08-20 |
EP3104890A1 (en) | 2016-12-21 |
RU2016135413A (ru) | 2018-03-14 |
KR20160110963A (ko) | 2016-09-23 |
US20180353495A1 (en) | 2018-12-13 |
BR112016014903A2 (pt) | 2017-08-08 |
BR112016014903A8 (pt) | 2018-05-02 |
AU2015216590A1 (en) | 2016-06-30 |
CA2937504A1 (en) | 2015-08-20 |
US20170165246A1 (en) | 2017-06-15 |
JP2017505345A (ja) | 2017-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015017629A (es) | Combinaciones farmaceuticas. | |
MX2019012884A (es) | Terapia de combinacion. | |
MX2014002471A (es) | Combinaciones sinergicas de los inhibidores de p13k y mek. | |
EP4218816A3 (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
IN2015DN00376A (es) | ||
EP4241850A3 (en) | Mdm2 inhibitors and combinations thereof | |
WO2015054619A8 (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
WO2015195848A8 (en) | Ezh2 inhibitors for treating lymphoma | |
MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
RU2014120792A (ru) | Способ лечения стромальных опухолей желудочно-кишечного тракта | |
EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
MX2015000746A (es) | Terapia de combinacion de inhibidores para el receptor del factor de crecimiento insulinico tipo 1 (igf1r) y fosfatidilinositol 3-cinasa (pi3k). | |
IN2015DN00450A (es) | ||
WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
PH12016502352A1 (en) | Pharmaceutical composition | |
JP2014525454A5 (es) | ||
TW201613578A (en) | Pharmaceutical combinations | |
EA025948B1 (ru) | КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR | |
WO2015035410A8 (en) | Cancer therapy | |
WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
RU2017111848A (ru) | Новая фармацевтическая композиция для профилактики и/или лечения недержания мочи | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
EA201270747A1 (ru) | Композиции и способы для профилактики и лечения ран | |
MX2015017058A (es) | Combinaciones farmaceuticas de un inhibidor de pi3k y un agente de desestabilizacion de microtubulos. | |
BR112015012497A2 (pt) | combinações farmacêuticas |